ONCOTARGETS AND THERAPY, vol.8, pp.1-5, 2015 (SCI-Expanded)
Article / Article
ONCOTARGETS AND THERAPY
Science Citation Index Expanded (SCI-EXPANDED), Scopus
advanced thyroid cancer, sorafenib, overall survival, PHASE-II TRIAL, ENDOTHELIAL GROWTH-FACTOR, DOUBLE-BLIND, INHIBITORS, CARCINOMA
Gazi University Affiliated:
Background: Antivascular endothelial growth factor tyrosine kinase inhibitors have been used recently in the treatment of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Off-label sorafenib is used in Turkey with special permission by the Ministry of Health for this indication.